323 Views | 136 Downloads
Corresponding author. 650 West 168th Street, Room 305, New York, NY 10032, USA. sk3295@columbia.edu (S.-H. Kuo).
See publication for full list of author contributions.
Dr. Zesiewicz has served as a clinical advisor for Steminent Biotherapeutics, and she has received travel reimbursement from the department of neurology at University of Southern Florida; has received travel reimbursement for a Biohaven Pharmaceuticals meeting.
Dr. Zesiewicz has served on the editorial board for Neurodegenerative Disease Management and Tremor and other Hyperkinetic Movements, and has received research support for her division for approximately 20 clinical trials for Parkinson’s disease, Friedreich’s ataxia, and spinocerebellar ataxias.
Dr. Zesiewicz’s division is a site in a multi-site trial of Parkinson’s disease patients with the LRRK2 mutation and is sponsored by the National Institutes of Health but funded by Emory University.
The rest authors report no conflicts of interest.
The CRC-SCA natural history study is supported by the Rare Disease Clinical Research Network (RDCRN) (RC1NS068897), and the National Ataxia Foundation.
Dr. Kuo has received funding from NINDS K08 NS08738 (principal investigator), Louis V. Gerstner Jr. Scholar Award, Parkinson’s Disease Foundation, American Academy of Neurology Research Fellowship, American Parkinson’s Disease Association (PG008011), International Essential Tremor Foundation, NIEHS pilot award ES009089, and the Smart Foundation.
The natural history study of spinocerebellar ataxias is supported by the Rare Disease Clinical Research Network (RDCRN) (RC1NS068897).
© 2017 Elsevier Ltd